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Abstract
Reduced endothelial nitric oxide synthase (eNOS) function has been linked to secondary complications of subarachnoid
hemorrhage (SAH). We previously found that there is increased eNOS function after SAH but that it is uncoupled, leading to
secondary complications such as vasospasm, microthromboembolism and neuronal apoptosis. Here we test the hypothesis
that recoupling eNOS with simvastatin can prevent these complications. SAH was created in mice that were treated with
vehicle or simvastatin starting 2 weeks before or 30 minutes after SAH. SAH increased phosphorylated eNOS which was
prevented by pre- or post-treatment with simvastatin. Simvastatin pre-treatment also prevented the increase in eNOS
monomer formation that was associated with SAH, decreased superoxide anion radical production and increased NO. These
changes were associated with decreased vasospasm, microthromboemboli and neuronal injury. The data suggest that
simvastatin re-couples eNOS after SAH, leading to decreased secondary complications such as vasospasm, micro-
thromboemboli and neuronal injury.
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Introduction
Subarachnoid hemorrhage (SAH) is associated with serious
secondary complications such as cerebral vasospasm, delayed
cerebral ischemia, cortical spreading ischemia and microthrom-
boembolism [1,2]. Theories for the development of cerebral
vasospasm and these associated secondary complications include
either the depletion or excess production of nitric oxide (NO). NO
is produced enzymatically by three nitric oxide synthase (NOS)
isoforms, namely endothelial, neuronal and inducible NOS or in a
non-enzymatic fashion via nitrate-nitrite redox reaction [3]. Under
physiological conditions endothelium-derived NO inhibits throm-
bosis and platelet adhesion and aggregation, endothelial cell
apoptosis, smooth muscle hypertrophy and leucocyte adhesion to
the endothelium [4]. Physiologically, eNOS is a homodimer that
facilitates NO production via electrochemical regulation of
electron flow into the ferrous-dioxygen complex. However, under
pathological conditions where blood vessels are exposed to
oxidative stress or depleted of cofactors such as tetrahydrobiop-
terin and L-arginine required for normal eNOS function, the
ferrous-dioxygen complex uncouples and electron flow may
generate superoxide anion radical (O2C) instead of NO [4]. It
has been demonstrated that the increased O2C can react with
endogenous NO to form peroxynitrite (ONOO
2), which exacer-
bates oxidative stress and facilitates eNOS uncoupling [5].
We recently demonstrated in mice that injection of blood into
the subarachnoid space induced uncoupling of eNOS and that this
was associated with secondary complications such as neuronal
apoptosis, microthromboembolism, cerebral vasospasm, oxidative
stress and reduced NO bioavailability [6]. We hypothesize that
this novel mechanism of eNOS uncoupling is a key mediator of the
secondary pathological changes of SAH. This study aims to obtain
more direct evidence for this mechanism and to determine effects
of alleviating it with a 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitor, simvastatin, which has been demonstrated to
improve endothelial function and reduce oxidative stress [7]. If this
hypothesis is correct, simvastatin, by eliminating oxidative stress,
would re-couple eNOS, restore NO availability and alleviate any




Experimental protocols were approved by the Institutional
Animal Care Committee. eNOS-lacZ mice were generated by
utilizing a murine eNOS promoter with the eNOS ATG site
mutated to prevent translation [8]. The promoter was then
coupled to a lacZ open reading frame. Mice were genotyped
using Southern blot analysis of genomic tail DNA. We used 60
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17062endothelial NOS-lacZ transgenic mice of both sexes weighing 19–
25 g (2 to 6 months old). Thirty mice (used for either histological
studies or molecular biology and biochemistry studies) were
randomly assigned to pre-SAH (15 mice) or post-SAH treatment
(15 mice) groups. Within each of the treatment groups, 7 to 8 mice
were assigned to be treated with simvastatin or vehicle.
SAH model and simvastatin treatment scheme
SAH was created as previously described with modifications [9].
To eliminate the inconsistency of time used to take blood from tail
and prevent coagulation of blood before injection, we induced
SAH by pre-chiasmatic cistern injection of non-heparinized blood
taken from hearts of donors with the same genetic background as
the transgenic mice (C57BL). For the pre-treatment group
(n=15), the animals were injected with simvastatin, 20 mg/kg
subcutaneously (dissolved in DMSO, then diluted with 0.9% NaCl
with a final concentration of DMSO of 10%), daily for 14 days
before the onset of SAH.
For the post-SAH simvastatin treatment group (n=15, the same
dose of simvastatin was injected 30 minutes after SAH creation,
and then daily for two days. For the vehicle group, treatment with
equivalent volumes of vehicle was administered daily for either 14
days or 2 days. Allocation to groups was sequential with a treated
and a vehicle animal operated each day. In some experiments, we
also included naive animals (C57BL) as untreated controls, which
were anaesthetized and euthanized as in other groups. Mice were
sacrificed 48 hours after surgery. They were perfused through the
left cardiac ventricle with NaCl, 0.9%, 10 ml, followed by 150 ml
4% paraformaldehyde in phosphate-buffered saline (PBS). Brains
were removed and fixed in 4% paraformaldehyde for 48 hours.
Brain blocks were embedded in paraffin. Sections 7 mm thick were
cut using a microtome (Leica, Wetzlar, Germany) for histological
studies.
Hematoxylin and eosin staining and vasospasm
measurement
The staining procedure was as described [6,9]. Paraffinized
sections were deparaffinized with xylene and rehydrated through a
decreasing gradient of ethanol solutions. Slides were stained with
hematoxylin and eosin, coverslipped with xylene-based mounting
medium (Permount, Sigma) and viewed under a light microscope.
Slides were scanned with a digital scanner (MIRAX scanner, Carl
Zeiss, Go ¨ttingen, Germany) and viewed with MIRAX software
(Zeiss). The lumen area and thickness of the middle cerebral artery
(MCA) was quantified by a blinded observer at 200x magnification
using Image J (National Institutes of Health [NIH], Bethesda,
MD). The sizes of images were calibrated based on their
magnification and MCA lumen was outlined using the free hand
tool to obtain lumen area. Artery wall thickness was measured at 4
equally spaced points along the artery circumference and averaged
to obtain artery thickness.
LacZ staining and detection
Brain sections were excised and dissected into 3 mm sections to
maximize surface area [6,8]. Sections were rinsed in PBS and then
immersed in fixative solution (0.2% glutaraldehyde, 2% formal-
dehyde, 5 mmol/L EGTA, 2 mmol/L MgCl2, and 100 mmol/L
Na2H2PO4, pH 7.3). Sections were again rinsed in PBS, blotted,
and immersed in aqueous X-Gal solution (1 mg/ml 5-bromo-
4chloro-3-indolyl-B-D-galactopyranoside, pH 7.3, Boehringer
Mannheim, Laval, Canada) for 16 hours in the dark at room
temperature. Tissue was embedded in paraffin, sectioned (7 mm)
and counterstained with neutral red (Sigma-Aldrich, St. Louis,
MO, USA) [8]. Localization and expression of b-galactosidase was
assessed by light microscopy by two independent observers blinded
to the type and group of the mice.
Peroxynitrite assay and anti-nitrotyrosine
Tissue sections were deparaffinized with xylene and dehydrated
in graded ethanol solutions. Antigen was retrieved by heating the
sections for 25 minutes in 0.01 mmol/L sodium citrate (pH 6.0) at
96uC [6]. Endogenous peroxidase activity was quenched by
incubating the sections for 30 minutes in 0.3% H2O2 in water.
Sections were blocked with 10% normal goat serum in PBS for 20
minutes to attenuate non-specific IgG binding. Polyclonal rabbit
anti-mouse nitrotyrosine antibody (rabbit polyclonal 1:200) was
used as a marker for peroxynitrite (ONOO
2) and was added to
the sections and incubated for 60 minutes. A secondary
biotinylated antibody (goat anti-rabbit) was added and specimens
for 30 minutes. The VIP reaction was then performed utilizing the
VECTASTAIN ABC Kit.
NO, superoxide anion radical detection
Superoxide anion radical (O2
2) and NO were detected in
homogenized fresh or deep frozen brain tissue using spectropho-
tometric methods [6]. The cell-permeable fluorophore 4,5-
diaminofluorescein-2-diacetate (DAF-2DA, Alexis Biochemicals,
Gruenberg, Germany) was used to detect NO and a chemilumi-
nescence probe, 2-methyl-6-(p-methoxyphenyl)-3,7-dihydroimi-
dazo[1,2-]-pyrazin-3-one (MCLA) for O2
2 detection. Homoge-
nized brain tissues were incubated with either 10 mmol/L DAF-
2DA for 30 minutes or 4 mmol/L MCLA in transparent 96-well
plates for 10 minutes (Fisher, Ottawa, ON, Canada) at room
temperature in the dark. DAF-2DA was excited at 495 nm and
emission read at 515 nm in a spectrofluorometer (SpectraMAX-
Gemini, Molecular devices, Sunnyvale, USA). The luminescence
signal of MCLA was read directly at 495 nm. All experiments
were repeated 3 times. To test the specificity of MCLA, increasing
concentrations of superoxide dismutase (SOD) (1–10 U/ml) was
used to reveal a concentration dependent MCLA luminescence
signal (data not shown). Since MCLA crosses cell membranes,
O2
2 was detected from both intra- and extracellular sources.
Western blots for eNOS and iNOS
Brain tissue (n=7–8 per group) was acutely excised and stored
at 280uC. Tissue was homogenized in 300 mL 1% RIPA buffer
with 0.1% protease inhibitor, and centrifuged at 13,000 rpm for
12 minutes at 4uC. Protein was quantified using the Bradford
method, where RIPA buffer was used as the blank standard. 30 mg
protein was loaded and separated by electrophoresis on 8%
sodium dodecyl sulphate - polyacrylamide gels (SDS-PAGE) and
transferred onto nitrocellulose membrane. We used Ponceau S
and Gel Code to stain the membrane and gel, respectively. Blots
were incubated with 5% milk for 60 minutes, followed by
incubation with primary monoclonal antibodies (1:1000 dilution)
against phosphorylated S1177-eNOS (BD Biosciences, San Jose,
CA, USA), eNOS (Cell signaling Danvers, MA, USA) and iNOS
(Abcam Inc, Cambridge, MA, USA). After washing in PBS,
membranes were incubated in horse radish peroxidase conjugated
goat anti-mouse antibody (Abcam) at a dilution of 1:1000 for 50
minutes at room temperature. Reactions were developed with
ECL reagent mix (Amersham Biosciences, UK). Protein intensities
were quantified by densitometric analysis utilizing Image J
software (NIH).
For eNOS monomer and dimer detection, we used low-
temperature SDS-PAGE [10,11]. Samples were subjected to SDS-
PAGE on 8% gels that were kept in an ice bath at 4uC. The gels
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membranes were incubated with primary antibodies against eNOS
(Cell Signalling Danvers, MA, USA) and the remainder of the
procedure was identical to the standard Western blot steps.
Immunohistological staining for fibrinogen, caspase-3
and NeuN
After deparaffinization and rehydration, antigen was retrieved
by heating the sections for 25 minutes in 0.01 mmol/L sodium
citrate (pH 6.0) at 96uC. For fibrinogen staining, endogenous
peroxidase activity was quenched by incubating the sections for 30
minutes in 0.3% H2O2 in water. Sections were blocked with 10%
normal goat blocking serum in PBS for 20 minutes and incubated
with fibrinogen first antibody (chicken anti-rat 1:200, Immunology
Consultants Laboratory, Newberg, OR) for 60 minutes. They
were washed with PBS and incubated with secondary biotinylated
anti-body (goat anti-chicken, Millipore) for 30 minutes. Staining
was visualized with VIP using the VECTASTAIN 7 ABC Kit
(Vector) and counterstained with 0.5% methyl green.
For caspase-3 and NeuN staining, after antigen retrieval,
sections were permeabilized with 0.3% Triton X-100 for 15
minutes and then incubated with 10% normal goat serum, 1%
bovine serum albumin and 0.1% sodium azide for 60 minutes.
Primary antibodies were monoclonal anti-NeuN (1:400, Invitro-
gen, Carlsbad, CA, USA) and rabbit anti-human active cleaved
caspase-3 (1:400, BD Pharmingen, Franklin Lakes, NJ, USA).
Secondary antibodies were Alexa Fluor 568 conjugated goat anti-
mouse for NeuN (1:1000, Invitrogen) and Alexa Fluor 488
conjugated goat anti-rabbit for caspase-3 (1:1000, Invitrogen).
After incubation, sections were cover slipped with anti-fading
mounting medium and sealed with nail polish. Slides were viewed
with a confocal microscope and images taken using constant
parameters.
TUNEL and Fluoro-Jade staining
Apoptosis was assessed using terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL, DeadEnd Fluro-
metric kit, Promega, WI, USA). Fluoro-jade B (Histo-Chem Inc,
Jefferson, AR, USA) staining was performed according to a
previously published protocol [9]. In brief, after deparaffinization
and subsequent rehydration, the slides were incubated in 0.06%
potassium permanganate (VWR International, Strasbourg,
France) for 15 minutes. Slides were then rinsed in deionized
water and immersed in 0.001% fluoro-jade B working solution
(0.1% acetic acid) for 30 minutes. Then they were washed and
dried in an incubator (60uC) for 15 minutes. Sections were cleared
in xylene and coverslipped with a non-aqueous, low fluorescence,
styrene based mounting medium (DPX, Sigma). Slides were
viewed under a confocal microscope and images taken using
constant parameters (laser power, exposure time and pinhole
size).
Statistical analysis and data quantification
All data are presented as means 6 standard deviation (SD).
Data were compared within groups over time and between groups
at each time by analysis of variance (ANOVA) or Student’s t-test
for continuous variables. P,0.05 was considered significant.
To keep the quantification on staining consistent, we pre-
determined five fixed symmetrical areas for cerebral cortex (three
for hippocampus) on a proper coronal section chart of the mouse
brain (Paxinos and Franklin, 2001). For fibrinogen staining (200x
magnification), we took one image from each fixed area (10 images
from cerebral cortex, 6 images from hippocampus) and counted all
microthromboemboli observed in the section. To determine
positive staining in TUNEL and casepase-3/NeuN stained
cerebral cortex, we used higher magnification (400x), and took 3
images from each of the fixed areas (30 images for both sides of
cerebral cortex). For the hippocampus, we counted all the positive
cells for TUNEL and caspase-3 staining, along all regions of the
hippocampus (dentate gyrus, CA3 and CA1) under microscope.
All counting was done by blinded researchers.
Results
Simvastatin down-regulates phosphorylated eNOS
X-gal staining was performed to localize the activity of LacZ/
eNOS in brains and cerebral arteries from these mice. We
previously found that X-gal staining was localized to the
endothelium of large arteries. SAH substantially increased the
expression of eNOS as compared to saline-injected controls [6]. In
the current study, we therefore compared end points between
simvastatin- and vehicle-treated mice with SAH.
In vehicle-treated animals, there was thick, dense LacZ staining
in the endothelial layer of the MCA (Fig. 1A). This was
significantly reduced by pre- or post-treatment with simvastatin
(Fig. 1A). We investigated this finding further using Western
blotting and found significant down-regulation of the expression of
the phosphorylated form of eNOS in both simvastatin-treated
groups (Figs. 1B, 1C and 1D). In the initial batch of experiments,
the expression of phosphorylated eNOS in naı ¨ve mice was
negligible (Fig. 1B); therefore we eliminated this group in the
subsequent experiments shown in Fig. 1C and 1D. Densitometry
quantification of phosphorylated eNOS was 2.060.2 and
10.462.2 for pre-SAH simvastatin-treated and vehicle-treated
animals, respectively (Fig. 1C, P,0.01). Phosphorylated eNOS
level was 1.160.1 for post-SAH simvastatin-treated and 9.164.5
for vehicle-treated animals (Fig. 1D, P,0.05).
Simvastatin increases eNOS dimer/monomer ratio and
NO production
We previously indirectly showed that SAH increased eNOS
expression and O2C concentration in the brain, but decreased NO
availability, suggesting uncoupling of eNOS [6]. We now used a
direct measurement of eNOS uncoupling, namely, eNOS dimer/
monomer ratio [10,11]. SAH was associated with a significant
increase in both eNOS dimer and monomer as compared to naı ¨ve
controls (Fig. 2C to 2F, P, 0.01). However, the relative proportion
of dimer, thus potentially functional eNOS, was significantly lower
in SAH than in naı ¨ve controls (eNOS dimer/monomer ratio was
5.960.4 and 4.060.3 for SAH, 16.566.9 and 15.563.8 for naive
controls in pre-treatment and post-treatment experiments, respec-
tively, Fig. 2A and 2B, P,0.01). Treatment with simvastatin
starting before SAH completely reversed the decreased ratio of
dimer/monomer to naı ¨ve level (P.0.05 compared to naı ¨ve group,
Fig 2A). In comparison, post-SAH treatment with simvastatin also
increased the dimer/monomer ratio as compared to vehicle
treatment but not to the level of naı ¨ve controls (P,0.05 compared
to naı ¨ve, Fig. 2B). This was directly related to the significantly
higher than normal level of monomer expression seen in the post-
SAH simvastatin-treated animals (P,0.05, Fig. 2E). Nevertheless,
all naive and simvastatin-treated animals had a significantly higher
dimer/monomer ratio than vehicle-treated SAH (P,0.01, Fig. 2A
and 2B).
The reversal towards normal of the eNOS dimer/monomer
ratio by simvastatin treatment correlated with increased NO
(Fig. 2J and 2K). Pre-SAH treatment completely restored NO
production to that in naı ¨ve level (Fig. 2J, P.0.05 compared to
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PLoS ONE | www.plosone.org 3 February 2011 | Volume 6 | Issue 2 | e17062Figure 1. Simvastatin decreases eNOS expression. A. Representative images of LacZ staining of the middle cerebral artery (MCA) from naı ¨ve,
vehicle, pre- and post-SAH simvastatin-treated animals. A thick densely stained LacZ positivity appears in the endothelial layer of the MCA from
vehicle animals (arrow heads). This is significantly reduced in both pre- or post-SAH treatment groups, to a similar level in naı ¨ve group. Scale bar is
50 mm. B. Quantification of phosphorylated eNOS from naı ¨ve, vehicle or simvastatin pre-SAH treated groups. Simvastatin treatment significantly
reduced phosphorylated eNOS almost to the same level in the naı ¨ve animals. A representative blot is shown for each group. C and D. Quantification
of phosphorylated eNOS from pre-SAH or post-SAH treated groups, respectively. Both pre- and post-SAH treatment significantly reduced
phosphorylated eNOS expression (P,0.01 for pre-treatment, P,0.05 for post-treatment). A representative blot is shown for each treatment group
under corresponding bar graphs. All data are mean 6 SD.
doi:10.1371/journal.pone.0017062.g001
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PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e17062Figure 2. Simvastatin increases eNOS dimer/monomer ratio and NO production. A and B. Dimer/monomer ratio of eNOS protein
expression for pre- and post-SAH treated groups, respectively. Pre-SAH treatment with simvastatin significantly increases dimer/monomer ratio to the
naı ¨ve level (P.0.05). Post-SAH treatment also markedly increases the ratio, but to a lesser extent (P,0.05 as compared to naı ¨ve controls). Vehicle
treated animals exhibit significantly lower dimer/monomer ratio than both naı ¨ve or the two simvastatin treated groups (P,0.01). C to F. Western blot
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SAH treatment with simvastatin partially restored NO production
(Fig. 2K, P,0.01 compared to naı ¨ve controls, but also P,0.05
compared to vehicle treated). Simvastatin not only prevented the
SAH-induced increase in eNOS dimer to naı ¨ve level (Fig 2D and
2F), but also effectively reduced eNOS monomer to (pre-treatment
Fig 2C) or near (post-treatment Fig 2E) the naı ¨ve level. These data
support the hypothesis that simvastatin re-couples eNOS to a
normal functional state.
Simvastatin reduces O2C, ONOOC and iNOS
SAH induces perivascular oxidative reactions probably mainly
due to oxidation of extravascular hemoglobin [12,13]. We found
that SAH increased O2C and ONOOC production and iNOS
expression, all of which may contribute to uncoupling of eNOS
[6]. Statins were shown to improve endothelial function and
reduce oxidative stress [7]. Here we found that simvastatin
treatment either given pre- or post-SAH markedly reduced O2C
(Fig. 3B for pre-SAH, P,0.001; 3C for post-SAH treatment,
P,0.01) and ONOOC production (Fig. 3A) as compared to
vehicle treatment. However, only pre-treatment of SAH with
simvastatin reduced O2C production to the naı ¨ve level (P.0.05
Fig. 3B). O2C production is still very high in post-SAH treated
mice compared to naı ¨ve (P,0.001 Fig. 3C). Similarly, only pre-
treatment of SAH with simvastatin reduced iNOS expression
(Fig. 3D for pre-SAH, P,0.01, 3E for post-SAH treatment,
P.0.05) as compared to vehicle.
These results show that SAH causes uncoupling of eNOS,
which in turn decreases NO availability, but increases O2C and
ONOOC concentrations in the brain. This mechanism may
contribute to secondary pathology associated with SAH such as
vasospasm, microthromboembolism and neuronal death [9]. We
tested this hypothesis by determining if simvastatin treatment
alleviates vasospasm, microthromboemboli and neuronal cell
death [1,2].
Simvastatin alleviates vasospasm and
microthromboembolism
Vasospasm of the anterior and MCA and microthromboemboli
throughout the brain are observed in the mouse model of SAH
[6,9]. In keeping with prior studies, we found that vehicle-treated
SAH animals had vasospasm of the MCA with a lumen/wall
thickness ratio of 4.761.7 (Fig. 4B). Both pre- and post-SAH
treatment with simvastatin alleviated vasospasm (lumen/wall
thickness ratio 17.866.3 for pre-treatment, 16.564.3 for post-
treatment, Fig. 4B, P,0.001 compared to vehicle). These are not
significantly different from that in naı ¨ve controls (19.863.3,
P.0.05 Fig. 4B). Microthromboemboli were detected by fibrin-
ogen staining and scattered throughout the brain in vehicle-treated
SAH animals (Fig. 4C to 4E). Both schemes of simvastatin
treatment eliminated most microthromboemboli in cerebral
cortex and hippocampal regions to naı ¨ve level (Fig. 4D for pre-
treatment, 4E for post-treatment, P,0.01,0.001 compared to
vehicle).
Simvastatin prevents neuronal death
To determine whether re-coupling eNOS with simvastatin
prevents neuronal death, we assessed brains of mice with SAH
treated with vehicle or simvastatin by TUNEL, caspase-3/NeuN
staining. Numerous TUNEL-positive neurons were observed in
the brains of vehicle-treated SAH mice (Fig. 5). Double-labelling
for caspase-3 and NeuN demonstrated a similar pattern of
localization and abundance of double positively stained neurons
in vehicle-treated animals as seen with TUNEL staining (Fig. 6).
The number of TUNEL positive neurons was significantly reduced
by treatment with simvastatin started before or after induction of
SAH (Fig. 5 and Fig. 7, P,0.01 except post-treatment in cortex).
Similarly, both pre- and post-SAH simvastatin treatment signif-
icantly reduced caspase-3/NeuN double positive neurons in
cerebral cortex and hippocampus in comparison to vehicle
treatment (Fig. 6 and Fig. 7, P,0.05,0.01).
Discussion
SAH is associated with oxidative stress due mainly to clot-derived
reactive oxygen species [14]. Secondary complications of SAH
include large-artery vasospasm, microthromboembolism and neuro-
nal injury, for which multiple mechanisms have been suggested [1,2].
We previously observed that experimental SAH was associated with
increased phosphorylation of Ser1177 in eNOS, but that this was
paradoxically accompanied by reduced NO [6]. This was suggestive
of eNOS uncoupling. Additionally, SAH was associated with
nitrosative stress as shown by increased O2C and nitrotryosine
deposits. We speculated that increased nitrosative stress along with
eNOS uncoupling further exacerbates oxidative stress and could be
importantincontributingtovasospasm,microthromboembolismand
neuronal injury [6]. In the present study we provide direct evidence
for eNOS uncoupling by demonstrating altered eNOS dimer/
monomer ratios in vehicle-treated mice with SAH in comparison to
naı ¨ve controls. SAH increased phosphorylated, activated eNOS,
decreased eNOS dimer and increased eNOS monomer expression.
The decreased eNOS dimer/monomer ratio provides direct evidence
of eNOS uncoupling after SAH. Both pre- and post-SAH treatment
with simvastatin reduced phosphorylation of Ser1177 eNOS and
eNOS monomer, suggesting restoration or recoupling of eNOS
function. Pre-treatment with simvastatin also abrogated the SAH-
induced increase in iNOS. This recoupling of eNOS is associated
with alleviation of vasospasm, neuronal apoptosis, microthromboem-
bolism, oxidative stress and restoration of NO/O2C balance. The
results suggest that eNOS activation and its uncoupling may be a key
factor in the pathogenesis of vasospasm and secondary complications
of SAH such as microthromboembolism [15]. Similar mechanisms
have been observed in vascular pathologies like diabetes, hyperten-
sion and thrombosis[4].In these conditions,oxidativestressmaybe a
quantification of separate monomer and dimer protein expression in pre- (C and D) and post-SAH (E and F) simvastatin treated animals. In pre-
treated animals, both eNOS monomer and dimer expression were decreased by simvastatin to the same level as in naı ¨ve animals. They were
significantly lower than that in vehicle treated animals (C and D, P,0.01 for both monomer and dimer). Similarly, in post-treated animals, both eNOS
monomer and dimer expression were decreased by simvastatin as compared to that in vehicle treated animals (P,0.01 for both). However, while
eNOS dimer was reduced by post-SAH treatment of simvastatin to the same level as in naı ¨ve animals (F), the eNOS monomer was still significantly
higher than that in naı ¨ve controls (E, P,0.05). Representative blots of monomer and dimer protein expression are shown in H (for pre-treatment) and
I (for post-treatment). Spectrometric measurement of NO shows pre-SAH treatment with simvastatin restored NO production to the level seen in
naı ¨ve controls, which is significantly higher than vehicle treated (J, P,0.01). In contrast, post-SAH simvastatin treated animals shows a significantly
increased NO production as compared to vehicle treated (K, P,0.05), but not to the same level as in naı ¨ve animals (K, P,0.01). All data are mean 6
SD. Legend in K is for all the charts in the figure.
doi:10.1371/journal.pone.0017062.g002
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nicotinamide adenine dinucleotide phosphate oxidases.
It is noticeable that when compared to the naı ¨ve controls, the
results seem a little difference between pre- and post-treatment
with simvastatin. The difference observed between the ratios from
pre- or post-SAH simvastatin groups could be that mice in pre-
SAH simvastatin treatment group were better equipped to deal
with oxidative stress and had a reduced expression of eNOS
Figure 3. Simvastatin decreases peroxynitrite, superoxide and iNOS production. A. Representative images of nitrotyrosine staining. In
vehicle treated animals, patches of densely stained nitrotyrosine appear in the brain parenchyma (arrow heads). In comparison, both simvastatin
treated groups show a substantial reduction in nitrotyrosine deposits. There is no nitrotyrosine deposit in the naı ¨ve group. Scale bar is 150 mm. B and
C. Spectrophotometric measurement of O2
2 shows markedly reduced production of O2
2 from pre-SAH (P,0.001) and post-SAH simvastatin treated
groups (P,0.01) as compared to vehicle treatment. However, only pre-SAH but not post-SAH simvastatin treatment reduce production of O2
2 to the
naı ¨ve level (P.0.05 for pre-SAH and P,0.001 for post-SAH compared to naı ¨ve controls). D and E. Western blot quantification of iNOS protein
expression show that iNOS protein was significantly decreased by pre- (D, P,0.01) but not post-SAH (E, P.0.05) simvastatin treatment as compared
to vehicle treated animals. A representative blot is shown for each treatment group under corresponding bar graphs. All data are mean 6 SD. Legend
in E is for all the charts in the figure.
doi:10.1371/journal.pone.0017062.g003
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PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e17062Figure 4. Simvastatin decreases cerebral vasospasm of the middle cerebral artery and reduces microthromboemboli after SAH. A.
Representative images showing vasospastic MCA in vehicle treated mice, as compared to larger diameter MCAs from the two simvastatin treated
groups that are similar to MCA in naı ¨ve group. Scale bar is 50 mm. B. Both pre- and post-SAH simvastatin treatment significantly increases the lumen
area/wall thickness ratio of MCA as compared to vehicle treatment (P,0.001). The ratios in both treatment groups are not different from that in naı ¨ve
control group (P.0.05). A small lumen area/wall thickness ratio indicates vasospasm. C. Representative images from immunohistochemical staining
of fibrinogen show the presence of numerous microthromboembli in SAH animals treated with vehicle (arrow heads) but only few in animals treated
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treatment was longer thus it is predicted that these animals are
likely to have maybe a more robust endothelium and be less likely
to suffer endothelial damage. In comparison, the post-treated
group has a slightly reduced dimer/monomer ratio, which is
caused by the relatively higher expression of eNOS monomers.
Despite the difference, post-treated animals had a significantly
higher ratio than that in placebo treated animals, indicating that
post-SAH treatment is still effective at preventing eNOS
uncoupling. Another major difference between the groups is that
oxidative stress remained moderately high in the post-SAH
simvastatin treated group as demonstrated from the sustained
expression of iNOS (Fig. 3E) and superoxide anion radical
(Fig. 3C). This could be due to the fact that statin therapy for only
Figure 5. Simvastatin reduces TUNEL positive cells after SAH. Representative images shown are from cerebral cortex. Vehicle-treated animals
show numerous TUNEL positive cells (F and L, arrow heads). In comparison, there are fewer positive cells in post-SAH simvastatin treated animals (O,
arrow heads), and almost no positive TUNEL positive cells in the pre-treatment mice (I), none in naı ¨ve mice (C). Scale bars are 200 mmi nA to C,
50 mmi nD to O.
doi:10.1371/journal.pone.0017062.g005
with simvastatin either pre- or post-SAH, and none in the naı ¨ve controls. Scale bar is 100 mm. D and E. Both pre-SAH and post-SAH treatment with
simvastatin significantly decrease microthromboemboli in both cerebral cortex (P,0.001) and hippocampus (P,0.01) as compared to vehicle treated
group. There was no significant difference between pre-SAH or post-SAH simvastatin treated groups as compared to naı ¨ve controls in either brain
regions quantified (P.0.05). All data are mean 6 SD.
doi:10.1371/journal.pone.0017062.g004
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effectively or fast enough to prevent most eNOS uncoupling, thus
making the dimer/monomer ratio level smaller due to the
prevalence of monomers. In the pre-SAH treatment group, a
longer treatment with simvastatin might confer protective effects
on the endothelium as previously documented, thus making its less
prone to oxidative damage and uncoupling. The prevention of
eNOS uncoupling would also reduce oxidative response and
incidence of thrombosis and cell death due to the increased
availability of NO and decreased reactive oxygen species.
Prior studies pretreated mice or rats with simvastatin and then
induced SAH using the endovascular perforation model [16–19].
Simvastatin was shown to alleviate vasospasm [16–19], reduce
cognitive dysfunction [20] and decrease inflammatory cell
infiltration [17]. The decrease in vasospasm is consistent with
the present results but prior studies found that treatment with
simvastatin beginning before SAH increased eNOS [16]. Howev-
er, post-SAH treatment with simvastatin decreased vasospasm and
improved neurobehavioral deficits but had no effect on eNOS
protein level. In contrast, Sugawara, et al., used the same post-
SAH simvastatin treatment scheme and the endovascular
perforation model in rats and reported that simvastatin not only
improved neurological deficits, but also increased the phosphor-
ylated form of eNOS without increasing total eNOS expression
[19]. We report that SAH increased eNOS dimer, monomer and
phosphorylated forms. However, the increased eNOS was
Figure 6. Simvastatin reduces caspase-3/NeuN positive cells after SAH. Representative images shown are from cerebral cortex. Vehicle
treated animals show numerous caspase-3/NeuN positive cells (F and L, arrow heads). In comparison, there are fewer positive cells in post-SAH
simvastatin treated animals (O), and almost no positive caspase-3/NeuN positive cells in the pre-treatment mice (I), none in naı ¨ve mice (C). Scale bars
are 100 mmi nA to C,5 0mmi nD to O.
doi:10.1371/journal.pone.0017062.g006
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uncoupling. Simvastatin, instead of increasing eNOS expression,
decreased the expression of eNOS to the naı ¨ve control level, and
increased NO production suggesting re-coupling of eNOS. Prior
studies did not examine eNOS monomer and dimer or NO
concentrations [16,19]. The discrepancy may be due to the
difference between species or the models since the endovascular
perforation model causes SAH associated with transient global
ischemia that may be greater than that occurring in the
prechiamatic injection model. In agreement with our suggested
hypothesis and mode of pathogenesis, other reports confirmed
some of our findings. Berra et al., found there was a significant
increase in iNOS and eNOS in patients with SAH compared to
controls, and that this increase was associated with poor clinical
condition [21]. Osuka et al., reported that SAH induced by
cisternal blood injection in rats was associated with an increase in
phosphorylated eNOS one and two days after SAH [22].
The current experiments suggest that SAH itself increases
eNOS rather than that vasospasm increases endothelial shear
stress which secondarily increases eNOS [14]. The mechanism of
increase is uncertain but may involve oxidative stress due to
perivascular blood. The increase in phosphorylated eNOS
consisted of both dimer and monomer although there was a
much greater increase in monomer than in dimer in vehicle-
treated SAH animals compared to naı ¨ve controls. Thus it is likely
that whatever eNOS is produced was constantly uncoupled.
Simvastatin decreased both eNOS dimer and monomer to or close
to levels seen in naı ¨ve mice indicating that simvastatin modulates
eNOS levels rather than simply up-regulating the protein as
previously reported [16,19]. During uncoupling, eNOS produces
O2C which reacts with endogenous NO producing ONOO
2. This
depletes NO resulting in microthromboembolism and vasospasm,
which in turn contribute to neuronal death.
Regarding the dose of simvastatin used in current study, we
adopted from McGirt et al [16], who utilized simvastatin to up-
regulate eNOS. Even though we did not examine the dose
responses, the dose used here is considered a high dose. However,
it falls within the clinical acceptable dose range that can be
administered to humans [16]. In experimental settings, Wang et
al., showed that high dose of simvastatin (10 and 30 mg/kg)
upregulates dopamine D1 and D2 receptors in the cerebral cortex
possibly through upregulation of eNOS in Sprague–Dawley rats
Figure 7. Quantification of TUNEL and caspase-3/NeuN positive cells in cerebral cortex and hippocampus. Pre-treatment of simvastatin
significantly reduces the number of both TUNEL (A, P,0.01 for both cortex and hippocampus regions) and caspase-3/NeuN positive cells (C, P,0.05
in hippocampus, P,0.01 in cortex) as compared to vehicle treatment. Similarly, post-treatment of simvastatin significantly reduces the number of
both TUNEL (B) and caspase-3/NeuN positive cells (D) in brain area of hippocampus (P,0.01 for TUNEL, P,0.05 for caspase-3/NeuN staining).
However, in cerebral cortex, post-treatment with simvastatin only markedly reduced the number of caspase-3/NeuN positive cells (D, P,0.01) but not
TUNEL positive cells (B, P.0.05). All data are mean 6 SD.
doi:10.1371/journal.pone.0017062.g007
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study (20 mg/kg for 14 days), Entres et al showed that simvastatin
has neuroprotective effects against cerebral ischemia in 129/SV
mice though upregulation of eNOS [24]. However, similar to
abovementioned studies, whether the upregulated eNOS is
monomer or dimer or a mixture of both is not known.
The molecular mechanisms underlying the beneficial effect of
simvastatin on eNOS are not known. Many potential mechanisms
warrant further investigation. It is known that BH4, a potent
naturally occurring reducing agent, plays a key role in dimmeriza-
tion of eNOS [4] [25]. Oxidative stress, which occurs after SAH,
may lead to excessive oxidation and depletion of BH4, which in
turn could result in uncoupling of eNOS. Other mechanisms such
as l-arginine deficiency, increased endogenous eNOS inhibitor
asymmetric dimethyl-L-arginine [26–27] or disruption of the zinc-
thiolate cluster [28] may all contribute to uncoupling of the
enzyme. The limitations of these experiments are that the
mechanism of eNOS activation after SAH remains to be
characterized, although candidate processes include vasospasm
[14] and increased oxidative stress [4], both of which occur after
SAH [12]. We observed elevated iNOS levels in the brain
parenchyma, which may contribute to oxidative stress, ONOO
2
formation, microthromboembolism and neuronal damage [29].
However, even when iNOS remained elevated in animals treated
with simvastatin after SAH, most of secondary complications were
decreased, suggesting iNOS may not play a major role in the
pathogenesis of vasospasm and other secondary complications
[21]. We also refer to microthromboembolism to describe fibrin
deposits in microvessels because it is not known if these form in situ
or embolize after being formed on the injured endothelium of
larger proximal arteries. Finally, statins have multiple biological
effects. They stabilize atherothrombotic plaques [30–32], reduce
inflammation and oxidative stress [33,34], reduce microvascula-
ture thrombosis and improve endothelial function [35,36]. These
effects are reported to be mediated by multiple mechanisms such
as direct scavenging of reactive oxygen species [37], inhibition of
expression of matrix metalloproteinases 2 (MMP-2) and MMP-9
[38,39] inhibition of protein isoprenylation, farnesylation and
geranylgeranylation [40]. The pleiotrophic effects of statins mean
that we cannot exclude other mechanisms by which they may have
alleviated secondary complications of SAH.
Clinical use of statins for the management of SAH is
controversial. Retrospective studies reported mixed results, with
three studies finding an increased risk of vasospasm or minimal
effect in statin-treated patients [11,13,41,42] and three primary
studies reporting a marked reduction in vasospasm[43] [17,44]
and a metaanalysis confirming the observed trend of vasospasm
reduction[45]. Additionally, two reported improved short-term
clinical outcome and decreased mortality, respectively [44,46].
Similar conflicting results were observed in randomized clinical
trials and metaanalyses [47]. It is likely that the variation in clinical
benefit is due to the small number of patients treated, and in type
of statin used, dose and timing of administration.
In conclusion, our results suggest simvastatin can re-couple
dysfunctional eNOS and restore NO/O2C balance, thus prevent-
ing secondary complications, such as vasospasm, microthrom-
boembolism and neuronal injury after SAH in mice. The results
also suggest that both pre- and acute post-treatment regimens may
be effective at alleviating eNOS uncoupling-associated complica-
tions. Furthermore, simvastatin restored eNOS levels to that of
naı ¨ve mice in terms of both dimer and monomer concentrations,
possibly indicating the importance of eNOS in the pathogenesis of
complications of SAH.
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